PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 29(Supplement_2): 28-31
2009
© 2009 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erixon, M.
Right arrow Articles by Kjellstrand, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erixon, M.
Right arrow Articles by Kjellstrand, P.

Part 2: Cellular and Molecular Biology of the Peritoneum and Peritoneal Dialysis

3,4-DIDEOXYGLUCOSONE-3-ENE IN PERITONEAL DIALYSIS FLUIDS INFUSED INTO THE PERITONEAL CAVITY CANNOT BE FOUND IN PLASMA

Martin Erixon1,2, Anders Wieslander1, Torbjörn Lindén1, Ola Carlsson1, Jan Åke Jönsson2, Ole Simonsen3 and Per Kjellstrand1

Gambro AB1 ; Analytical Chemistry,2 University of Lund; and University Hospital of Lund,3 Lund, Sweden

Correspondence to: M. Erixon, Gambro AB, Box 10101, S-220 10 Lund, Sweden. martin.erixon{at}gambro.com

{diamondsuit} Objective: Glucose degradation products (GDPs) are important for the outcome of peritoneal dialysis (PD) treatment. The most cytotoxic GDP found in conventionally manufactured fluids, 3,4-dideoxyglucosone-3-ene (3,4-DGE), may in addition be recruited from 3-deoxyglucosone (3-DG). What happens with the GDPs in the fluid infused into patients during PD is not known. We investigated whether 3,4-DGE and 3-DG in PD fluid can be found in plasma during treatment.

{diamondsuit} Design: Patients on PD were dialyzed with a conventional PD fluid containing 43 µmol/L 3,4-DGE and 281 µmol/L 3-DG. Parallel experiments were performed in rats and in vitro with human plasma. The rats were dialyzed with a PD fluid containing 100 µmol/L 3,4-DGE and 200 µmol/L 3-DG.

{diamondsuit} Results: The 3,4-DGE concentration in the peritoneum declined at a much higher rate during the dwell than did the 3-DG concentration. However, 3,4-DGE was not detected in the plasma of patients or of rats during dialysis. The 3-DG concentration in plasma peaked shortly after infusion of fluid into the peritoneal cavity. The 3,4-DGE concentration during experimental incubation in plasma declined rapidly; the 3-DG concentration declined only 10% as rapidly (or less).

{diamondsuit} Conclusion: During dialysis, 3,4-DGE could not be detected in plasma of either PD patients or rats, presumably because of its high reactivity. On the other hand, 3-DG may pass through the membrane and be detected in the blood.

KEY WORDS: Peritoneal dialysis fluid; glucose degradation products; 3,4-DGE; 3-DG; plasma; advanced glycation end-products.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 2009 by Multimed Inc.